Psychometric validation of the Dutch translation of the quality of life in reflux and dyspepsia (QOLRAD) questionnaire in patients with gastroesophageal reflux disease

• Published in: Health and quality of life outcomes Vol. 8; no. 1; p. 85
• Main Authors: Engels, Leopold G J B, Klinkenberg-Knol, Elly C, Carlsson, Jonas, Halling, Katarina
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 17.08.2010; BioMed Central; BMC
• Subjects: Adolescent; Adult; Care and treatment; Clinical medicine; Dyspepsia; Dysphagia; Family medical history; FDA approval; Female; Gastroesophageal Reflux; Health aspects; Hospitals; Humans; Likert scale; Male; Middle Aged; Netherlands; Outpatients; Patient outcomes; Patient satisfaction; Psychometrics; Quality of Life; Questionnaires; Reproducibility of Results; Risk factors; Sickness Impact Profile; Sleep; Studies; Surveys; Surveys and Questionnaires; Translations; Young Adult; Netherlands; Sweden
• ISSN: 1477-7525; 1477-7525
• DOI: 10.1186/1477-7525-8-85

The Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire is one of the best-characterized disease-specific instruments that captures health-related problems and symptom-patterns in patients with gastroesophageal reflux disease (GERD). This paper reports the psychometric validation of a Dutch translation of the QOLRAD questionnaire in gastroenterology outpatients with GERD. Patients completed the QOLRAD questionnaire at visit 1 (baseline), visit 2 (after 2, 4 or 8 weeks of acute treatment with esomeprazole 40 mg once daily), and visit 4 (after 6 months with on-demand esomeprazole 40 mg once daily or continuous esomeprazole 20 mg once daily). Symptoms were assessed at each visit, and patient satisfaction was assessed at visits 2 and 4. Of the 1166 patients entered in the study, 97.3% had moderate or severe heartburn and 55.5% had moderate or severe regurgitation at baseline. At visit 2, symptoms of heartburn and regurgitation were mild or absent in 96.7% and 97.7%, respectively, and 95.3% of patients reported being satisfied with the treatment. The internal consistency and reliability of the QOLRAD questionnaire (range: 0.83-0.92) supported construct validity. Convergent validity was moderate to low. Known-groups validity was confirmed by a negative correlation between the QOLRAD score and clinician-assessed severity of GERD symptoms. Effect sizes (1.15-1.93) and standardized response means (1.17-1.86) showed good responsiveness to change. GERD symptoms had a negative impact on patients' lives. The psychometric characteristics of the Dutch translation of the QOLRAD questionnaire were found to be satisfactory, with good reliability and responsiveness to change, although convergent validity was at best moderate.